[go: up one dir, main page]

MX2010010873A - Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva. - Google Patents

Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva.

Info

Publication number
MX2010010873A
MX2010010873A MX2010010873A MX2010010873A MX2010010873A MX 2010010873 A MX2010010873 A MX 2010010873A MX 2010010873 A MX2010010873 A MX 2010010873A MX 2010010873 A MX2010010873 A MX 2010010873A MX 2010010873 A MX2010010873 A MX 2010010873A
Authority
MX
Mexico
Prior art keywords
udenafil
alfuzosin
oxybutynin
treatment
combination
Prior art date
Application number
MX2010010873A
Other languages
English (en)
Inventor
Giuliano Francois
Behr-Roussel Delphine
Original Assignee
Pelvipharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelvipharm filed Critical Pelvipharm
Publication of MX2010010873A publication Critical patent/MX2010010873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una combinación específica de dos agentes activos: udenafil y uno de alfuzosin y oxibutinina, y a su uso para el tratamiento de la vejiga hiperactiva.
MX2010010873A 2008-04-02 2009-04-02 Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva. MX2010010873A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4167108P 2008-04-02 2008-04-02
EP08300170A EP2106792A1 (en) 2008-04-02 2008-04-02 Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
PCT/EP2009/053951 WO2009121929A1 (en) 2008-04-02 2009-04-02 Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.

Publications (1)

Publication Number Publication Date
MX2010010873A true MX2010010873A (es) 2011-03-04

Family

ID=39739354

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010873A MX2010010873A (es) 2008-04-02 2009-04-02 Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva.

Country Status (12)

Country Link
US (1) US20110021542A1 (es)
EP (2) EP2106792A1 (es)
JP (1) JP2011517678A (es)
KR (1) KR20110005836A (es)
CN (1) CN102046163A (es)
AU (1) AU2009232027A1 (es)
BR (1) BRPI0911169A2 (es)
CA (1) CA2720410A1 (es)
IL (1) IL208385A0 (es)
MX (1) MX2010010873A (es)
RU (1) RU2010144795A (es)
WO (1) WO2009121929A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010115647A (ru) * 2007-10-02 2011-11-10 Донг-А Фарм.Ко., Лтд. (Kr) Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
EA201291298A1 (ru) * 2010-06-22 2013-09-30 Тева Вимен'С Хелс, Инк. Интравагинальные устройства, содержащие антихолинергические агенты, и способы их изготовления
UA118110C2 (uk) * 2013-06-28 2018-11-26 Ханмі Фарм. Ко., Лтд. Фармацевтичний комбінований склад капсули, який містить тадалафіл і тамсулозин
CN114796496B (zh) * 2022-05-09 2023-06-23 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 交感神经活化抑制剂和/或α1-肾上腺素能受体抑制剂在制备治疗干眼症的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
RU2008120332A (ru) * 2005-12-20 2010-01-27 Пфайзер Продактс Инк. (Us) Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
WO2007113243A2 (en) 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder

Also Published As

Publication number Publication date
CN102046163A (zh) 2011-05-04
JP2011517678A (ja) 2011-06-16
BRPI0911169A2 (pt) 2017-06-20
IL208385A0 (en) 2010-12-30
RU2010144795A (ru) 2012-05-10
EP2285370A1 (en) 2011-02-23
KR20110005836A (ko) 2011-01-19
AU2009232027A1 (en) 2009-10-08
US20110021542A1 (en) 2011-01-27
EP2106792A1 (en) 2009-10-07
WO2009121929A1 (en) 2009-10-08
CA2720410A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
MX2011006150A (es) Compuestos inhibidores de cinasa.
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
IN2012DN01869A (es)
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
IN2012DN00624A (es)
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
IN2014CN04014A (es)
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2011097522A3 (en) Combination methods for treatment of disease
MX2010010873A (es) Uso de una combinacion de udenafil y alfuzosin u oxibutinina para el tratamiento de la vejiga hiperactiva.
PT3330383T (pt) Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
MY155340A (en) Use of cathepsin c
PH12013500392A1 (en) Theobromine in combination with an expectorant or a mucolytic for use in therapy
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
MX2010004259A (es) Tratamientos antitumorales mejorados.
EP3449917A3 (en) Tapentadol for preventing chronification of pain
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
MY179784A (en) Use of cathepsin h
GB2471641A (en) Inhibitors
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA41660U (en) Use of jacton and mexidol as actoprotector

Legal Events

Date Code Title Description
FA Abandonment or withdrawal